Company Of The Day: Merck
What?
Merck (NYSE:MRK) posted a stronger than expected set of Q3 2021 results, with revenue rising by about 20% year-over-year to $13.15 billion and adjusted EPS rising 28% to $1.75. The company also raised its full-year revenue guidance to between $47.4 billion and $47.9 billion.
Why?
Relevant Articles
- After A 30% Fall In A Year Is Pfizer Stock A Better Pick Over Merck?
- At $100 Does Merck Stock Have Room For Growth?
- Should You Pick Merck Stock Over Coca-Cola?
- Should You Buy Merck Stock After An Upbeat Q2?
- How Has Merck Stock Performed During The 2022-23 Inflation Shock?
- Is Merck Stock A Better Pick Over ABBV?
Growth was driven by strong demand for drugs including Keytruda, Gardasil, and animal health products.
So What?
Merck stock gained almost 6% in Thursday’s trading.
See Our Complete Analysis For Merck
What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since 2016.
Invest with Trefis Market Beating Portfolios
See all Trefis Price Estimates